Phase Ill TAILORx Trial Results in Node Negative, Hormone-Receptor Positive, HER2 Negative Breast Cancer: Implications for Clinical Practice

Lori J. Goldstein, MD, Fasco
Professor, Medical Oncology I Director, Naomi and Phil Lippincott Breast Evaluation Center I Chief, Breast Service I Deputy Associate Director of Clinical Research I Fox Chase Cancer Center Temple Health, Philadelphia, USA